Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML (clinicaltrials.gov) - Oct 9, 2026 - P1 | N=24 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Targeted Protein Degradation • FLT3 • KMT2A • NPM1
|